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Drugs designed to reach a pharmacological CNS target must be effectively transported across 25 
the blood-brain barrier (BBB), a thin monolayer of endothelial cells tightly attached together 26 
between the blood and the brain parenchyma. Because of the lipidic nature of the BBB, 27 
several physicochemical partition models have been studied as surrogates for the passive 28 
permeation of potential drug candidates across the BBB (octanol-water, alkane-water, 29 
PAMPA…). In the last years, biopartition chromatography is gaining importance as a 30 
noncellular system for the estimation of biological properties in early stages of drug 31 
development. Microemulsions (ME) are suitable mobile phases, because of their ease of 32 
formulation, stability and adjustability to a large number of compositions mimicking 33 
biological structures. In the present work, several microemulsion liquid chromatographic 34 
(MELC) systems have been characterized by means of the Abraham’s solvation parameter 35 
model, in order to assess their suitability as BBB distribution or permeability surrogates. In 36 
terms of similarity between BBB and MELC systems (dispersion forces arising from solute 37 
non-bonded electrons, dipolarity/polarizability, hydrogen-bond acidity and basicity, and 38 
molecular volume), the passive permeability surface area product (log PS) for  neutral 39 
(including zwitterions), fully and partially ionized drugs was found to be well correlated with 40 
the ME made of 3.3% SDS (w/v; surfactant) 0.8% heptane (w/v; oil phase) and 6.6% 1-41 
butanol (w/v; co-surfactant) in 50 mM aqueous phosphate buffer, pH 7.4. 42 
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1. Blood-brain barrier 53 
1.1. Experimental models: log BB and log PS 54 
The blood–brain barrier (BBB) plays a fundamental role in the pharmacological activity of 55 
drugs targeting the central nervous system (CNS). It is a thin monolayer of endothelial cells, 56 
tightly attached together, that separates the circulating blood and the brain parenchyma.  57 
Two different in vivo BBB experimental models have been considered in the present 58 
work, the plasma-to-brain distribution ratio (log Kp, also known as log BB) and the 59 
permeability-surface area product (PS). Kp accounts for the concentration of drug present in 60 
the brain at steady state in relation to that in plasma. This is, in fact, a partition coefficient 61 
between the concentrations of both bound and unbound drug in brain (intracellular and 62 
interstitial fluids) and plasma. In vivo, log BB is determined at a specific time point after drug 63 
administration. It should be pointed out that bound drug molecules (for instance, to plasma 64 
and cytoplasmic proteins) are not expected to be pharmacologically active [1]. Therefore, 65 
besides BBB equilibration of unbound drug molecules, log BB measures nonspecific binding 66 
to brain tissue and plasma proteins. Consequently, in the case of drug molecules significantly 67 
bound to cytoplasmic proteins in brain, log BB might fail to indicate the effective extent of 68 
BBB penetration [2]. However, log BB is a widely used parameter in BBB studies, especially 69 
for in silico predictions of BBB in vivo data [3,4]. 70 
In contrast to log BB, in situ brain perfusion experiments, mainly performed on 71 
rodents, allow the measurement of the initial and unidirectional rate of brain penetration from 72 
blood, or usually from saline, to brain across the luminal BBB membrane, even in the case of 73 
solutes strongly bond to proteins. Perfusion time is about 30 to 180 s [5], and it ends before 74 
any equilibrium state can be reached. In this way, the clearance or Kin (mL g-1 s-1, mL of 75 
perfusate per gram of brain tissue and second of net perfusion time) is determined. However, 76 
this parameter depends on the perfusion flow velocity and, therefore, Kin is corrected by the 77 
flow of the perfusion fluid in brain, measured by an appropriate flow calibrant, such as 78 
radioactive iodoantypirine, microspheres or diazepam [6]. Thus, PS is obtained, by the 79 
product of luminal permeability (cm s-1) and the endothelial surface area per gram of brain 80 
tissue (cm2 g-1).  81 
 82 
1.2. Factors affecting the distribution and permeation between blood and brain: a LFER 83 
approach 84 
log BB was extensively studied by Abraham and coworkers [7,8] by means of linear free 85 
energy relationships (LFER) in order to point out the factors that influence the distribution of 86 
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solutes between blood and brain. According to the solvation model for unionized molecules 87 
[9], a solute dependent variable (log SP) is linearly related to specific interactions between 88 
solute and surrounding phase, mainly dispersion (e·E), dipole-dipole or dipole-induced dipole 89 
plus some polarizability interactions (s·S), solute hydrogen-bond acidity and basicity (a·A and 90 
b·B, respectively), and a volume term (v·V) related to the work of separating solvent 91 
molecules to provide a cavity of suitable size for the solute molecule and solute-solvent 92 
general dispersion interactions: 93 
log SP = c + eE + sS + aA + bB + vV  (1) 94 
where E, S, A, B, and V are solute descriptors, and e, s, a, b, and v are system constants 95 
reflecting differences between the two condensed phases being studied, in the present case 96 
blood and brain. Thus, a set of 157 substances with directly measured and indirectly 97 
determined log BB values was studied yielding the following equation [8]: 98 
2
log BB = 0.044 0.511 0.886 0.724 0.666 0.861
( 148, 0.710, SD 0.367, 71)
+ E  S A B + V
n R F
  
     (2) 99 
At the time of its publication in 2001, due to the size of the set and chemical diversity 100 
of the selected molecules, this was a good general blood-brain distribution model, which 101 
revealed the factors of brain uptake. Provided that solute descriptors are zero or positive, large 102 
and positive coefficients increase log BB, which means, in turn, a higher affinity for brain. 103 
Thus, according to Eq. (2), solutes interacting through π- and n-electron pairs (e·E > 0) and 104 
large molecules (v·V > 0) show higher brain uptakes, whereas dipolar or polarizable solutes 105 
(s·S < 0) with hydrogen-bond interactions (a·A, b·B < 0) tend to remain in the blood phase. 106 
The relatively low determination coefficient in Eq. (2) might be due to the difficulty of 107 
accurate experimental determination of log BB values, and the molecular descriptors used, 108 
either experimentally measured or calculated, referred to neutral solutes. 109 
 In a later study in 2004 [10], Eq. (1) was applied to 30 log PS values of neutral 110 
compounds, leading to the following equation for permeation from saline (standard deviations 111 
of the coefficients are reported in brackets): 112 
2
log PS = 0.639(0.408) 0.312(0.515) 1.009(0.158) 1.895(0.385)
1.636(0.410) 1.709(0.392) ( 30, 0.870, SD 0.52, 32.2)
  
    
+ E  S A 
B + V n R F  (3) 113 
It should be stressed that acidic or basic compounds that could be totally or partially 114 
ionized at the physiological pH of 7.4 were not included in that analysis, although carboxylic 115 
acids could be included in the log BB model of Eq. (2) by introduction of a correction factor 116 
[8]. In a later work, acids and bases totally ionized were also included in log PS correlations 117 
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[11]. A comparison of the coefficients in Eqs. (2) and (3) reveals that, qualitatively, blood-118 
brain distribution and permeation are ruled by the same factors.  119 
 120 
1.3. MELC as a physicochemical method for the determination of biological activity 121 
Beyond ethical concerns in animal experimentation, in early stages of the drug discovery 122 
process an accurate in vivo determination of biological activity for a large number of potential 123 
candidates is unaffordable. Thus, isotropic organic solvent/water partition models (octanol, 124 
hexadecane…) were studied as physicochemical surrogates of BBB [5]. However, simple 125 
partition coefficients like octanol-water were unable to model the desolvation (breaking of the 126 
hydrogen-bounds between a solute and the solvating water molecules) involved in the transfer 127 
of compound from aqueous solution into a phospholipid bilayer. The combination of partition 128 
coefficients measured in octanol-water and alkane-water allowed the inclusion of hydrogen-129 
bonding interactions, improving the prediction capacity of the model, but increasing the time 130 
required to carry out the determination. For screening purposes the measurement of several 131 
partition coefficients for a single molecule is excessively time consuming, and thus faster 132 
approaches are desirable. 133 
Microemulsion liquid chromatography (MELC) is a very interesting technique, 134 
especially in the field of pharmaceutical analysis, because of the ability of the microemulsions 135 
(ME) used as mobile phases to solubilize both lipophilic and hydrophilic compounds and its 136 
separation capabilities [12,13]. Oil-in-water ME are made of oil droplets (octane, heptane…) 137 
stabilized by a surfactant (SDS, sodium cholate, Brij 35…) and a cosurfactant (a short-chain 138 
alcohol as 1-butanol, 1-pentanol…) and dispersed in an aqueous buffer. The anionic SDS is 139 
commonly used as surfactant in a concentration range of 2-3%, and typically the amount of 140 
oil is frequently below 1% [12,13]. When linear alkanes are involved in the ME, the mass 141 
ratio between SDS and the cosurfactant is suggested to be 0.5 [14]. For such systems, the oil-142 
in-water ME strongly depends on the salt concentration and it can only exist in a relatively 143 
small water-rich range of compositions [15,16]. Once prepared, ME are stable and variations 144 
in their composition (pH, buffer nature, surfactant type and concentration…) do not 145 
significantly change their functionality [17]. However, retention mechanisms in MELC 146 
systems are complex, since solutes are expected to partition at least between the bulk aqueous 147 
phase, the oil droplet, and the surfactant-coated stationary phase [18].  148 
Furthermore, and this is the main point of this study, ME can be used as 149 
physicochemical surrogate models of biological processes, such as lipophilicity [19–21] or 150 
BBB [22–24], since ME mimic, to some extent, the properties of cell membranes. Liu and 151 
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coworkers [22], following a LFER approach, characterized several MELC systems and 152 
compared them to biological ones. The authors concluded that a C18 stationary phase and a 153 
ME mobile phase consisting of 3.3% SDS, 6.6% butanol, 1.6% heptane and 88.5% 50 mM 154 
phosphate buffer pH 7.0 (all percentages in weight) was a good surrogate of BBB distribution, 155 
particularly log BB. However, Liu and coworkers [22] studied only 37 compounds, six of 156 
which were left out as outliers. 157 
The purpose of this study is the comparison of several MELC systems to BBB systems 158 
by means of the Abraham model in order to find appropriate MELC systems for surrogation 159 
of BBB systems. Since in principle the Abraham model was derived for non ionic 160 
compounds, a further goal is to check the performance of MELC surrogation for drugs that 161 
should be totally or partially ionized drugs at the blood physiological pH.  162 
 163 
2. Material and methods 164 
2.1. Instrumentation 165 
pH measurements were taken with a Crison (Barcelona, Spain) 5014 combination electrode 166 
(glass electrode and a reference electrode with a 3.0 M KCl solution in water as salt bridge) in 167 
a Crison GLP22 pH meter. MEs were sonicated in a J.P. Selecta (Barcelona, Spain) ultrasonic 168 
bath with a power of 360 W. 169 
HPLC measurements were performed on a Shimadzu (Kyoto, Japan) HPLC system 170 
consisting of two LC-10ADvp pumps, a SIL-10ADvp auto-injector, an SPD-M10Avp diode 171 
array detector, a CTO-10ASvp oven at 37 °C and a SCL-10Avp controller. A 5 μm 150 x 4.6 172 
mm Gemini C18 column and a 4 x 3.0 mm guard cartridge from Phenomenex (Torrance, CA, 173 
USA) were used at a flow rate of 1.0 mL min−1. Each compound was analyzed at least in 174 
triplicate and injection volumes were set to 10 μL. Retention factors were expressed as log k = 175 
log ((tR −t0)/t0), where tR and t0 were the retention times of analyte and potassium bromide 176 
(Merck, for analysis) as dead timer marker, respectively. 177 
 178 
2.2 Mobile phase and sample preparation 179 
Water was deionized to a resistivity of 18.2MΩ cm by the Milli−Q plus system from 180 
Millipore (Billerica, MA, USA). Aqueous buffer was prepared from sodium 181 
dihydrogenphosphate (Merck, 99%) and sodium hydrogenphosphate (J. T. Baker, 99.5%) to a 182 
final concentration of 50 mM and pH 7.4. Under magnetic stirring and at room temperature, 183 
3.3% w/v of SDS (Sigma-Aldrich, > 99%) was dissolved in aqueous buffer until a transparent 184 
colorless solution was obtained. Then pH was adjusted to 7.4 by the addition of small 185 
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volumes of a 3 M NaOH solution prepared shortly before use from pellets (Merck, > 99%), 186 
followed by the addition of 6.6% w/v 1−butanol (Sigma−Aldrich, 99.8%) and the desired 187 
amount of heptane (0%, 0.8% or 1.6% w/v; Merck, for analysis). At this point, the solution 188 
became white and turbid. Magnetic stirring was maintained for 10 min and the desired ME 189 
volume was adjusted with aqueous buffer (in order to compensate the volume contraction of 190 
the mixture). Then the ME was sonicated for about 30 min until it became clear again, and 191 
finally the solution was left to stand at room temperature for at least 12 h. Immediately before 192 
use, ME was vacuum filtered using a Büchner funnel and a 0.45 μm nylon membrane 193 
(Teknokroma, Spain).  194 
 Injected compounds were provided by Abbott Laboratories (Abbot Park, IL, USA), 195 
Acros Organics (Geel, Belgium), Astrazeneca (London, UK), Baker (Center Valley, PA, 196 
USA), Boehringer Ingelheim Pharmaceuticals (Ridgefield, CT, USA), Carlo Erba (Milano, 197 
Italy), Esteve (Barcelona, Spain), Janssen (Beerse, Belgium), Merck (Billerica, MA, USA), 198 
Roche (Basel, Switzerland), Scharlau (Barcelona, Spain), Sigma–Aldrich (St. Louis, MO, 199 
USA), and Toronto Research Chemicals (Toronto, ON, Canada); all of high purity grade 200 
(≥97%). 10 mg mL-1 stock solutions were prepared in methanol (Fisher, HPLC grade) and 201 
ten-fold diluted with ME before injection.  202 
 203 
2.3 HPLC and column cleaning 204 
After a working session, in order to avoid the precipitation of SDS, the HPLC instrument and 205 
column were washed at a flow rate of 1 mL min-1 with water/methanol 95:5 followed by 206 
water/methanol 5:95, 30 min each.  207 
 208 
3. Results and discussion 209 
3.1. LFER characterization of BBB permeability 210 
A new LFER characterization study according to Eq. (1) was conducted which broadens the 211 
chemical diversity of test compounds in relation to Eq. (3). The study was based in the in situ 212 
rodent brain perfusion permeability data referred to permeation from saline at pH 7.4 and 213 
corrected for ionization, compiled by Avdeef [5]. Molecules were selected that exhibited BBB 214 
passive permeation only, avoiding carrier-mediated or actively transported processes. 215 
Therefore, the solvation property selected for this study was the so called intrinsic passive 216 
permeability (log P0BBB). In fact, log P0BBB is just a correction of log PS for ionized 217 
compounds and therefore log P0BBB = log PS in the case of non-ionized species. Observed log 218 
P0BBB values obtained from experiments with rats were correlated with measured (when 219 
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available) or calculated molecular descriptors [25] (see Table 1), according to Eq. (1) then the 220 
fitted coefficients were used to back calculate BBB0log P  values, and finally a linear regression 221 
was established between observed and predicted BBB0log P  values. In this work, compounds 222 
with residuals higher than twice the standard deviation of the regression were considered as 223 
outliers. After excluding these values from correlations, the final coefficients obtained are 224 




log  = 4.048(0.139) 0.213(0.133) 0.947(0.126) 0.438(0.150)
1.497(0.163) 1.953(0.133) ( 141, 0.833, SD 0.64, 135)
P + E  S A 
B + V n R F
  
    
 (4) 226 
It is noteworthy that Eq. (4) covers a wide range of permeability values (about 7 log 227 
units) and includes molecules with different chemical properties as reflected by their 228 
descriptors (Table 1).  229 
 230 
3.2. LFER characterization of MELC systems 231 
With the aim of exploring the predictive capacity of MELC systems for the prediction of BBB 232 
distribution or permeability, three different mobile phases were prepared from 50 mM 233 
phosphate buffer pH 7.4 containing the same SDS and 1-butanol concentration (3.3% and 234 
6.6% w/v, respectively) but with different amounts of heptane (0, 0.8, and 1.6% w/v). Test 235 
compounds (Table 2) were selected to present different chemical characteristics (hydrogen-236 
bonding interactions, dipolarity/polarizability…) and to be unionized at the desired pH in 237 
order to build the correlations between log k and neutral molecular descriptors. The column 238 
temperature was set to 37ºC because this is the physiological temperature. One additional 239 
advantage of 37ºC over room temperature is the higher the temperature, the lower the mobile 240 
phase viscosity and consequently the instrumental backpressure. Once outliers were excluded 241 
(Figure 2), the following equations were obtained: 242 
1.6% heptane
2
log  = 0.179(0.059) 0.011(0.052) 0.418(0.072) 0.283(0.099)
1.148(0.074) 1.203(0.095) ( 46, 0.938, SD 0.15, 122)
k E  S A 
B + V n R F
  




log  = 0.186(0.053) 0.010(0.046) 0.411(0.062) 0.237(0.086)
1.133(0.064) 1.231(0.082) ( 45, 0.952, SD 0.13, 153)
k E  S A 
B + V n R F
  




log  = 0.197(0.052) 0.015(0.039) 0.353(0.056) 0.167(0.086)
1.196(0.059) 1.202(0.081) ( 41, 0.959, SD 0.11, 163)
k E  S A 
B + V n R F
  
    
 (7) 245 
Interestingly, both ME (Eq. (5) and (6)) show nearly identical system coefficients 246 
despite the different concentration of heptane, and they are even similar to the micellar system 247 
without heptane (Eq. (7)). Apparently the oil phase slightly favors interactions with 248 
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dipolar/polarizable solutes with hydrogen-bonding acidity properties, whereas the micellar 249 
phase shows somewhat affinity for molecules with hydrogen-bonding basicity. 250 
 251 
3.3. Comparative study 252 
A very interesting tool for the quantification of the similarity between two systems is the 253 
euclidean distance (d) of their characteristic vectors [26]. e, s, a, b, and v coefficients on Eq. 254 
(1) define the properties of a particular system, and they can be considered as the elements of 255 
a five-dimensional vector. When the comparison is established between vectors of different 256 
magnitudes, for instance log BB and log k, it is convenient to divide the elements by the 257 
length of the vector to obtain unit vectors (eu, su, au, bu, and vu, Table 3), and then calculate 258 
the distance (Table 4). Complementarily, a plot of the two principal components (PC) 259 
obtained after a PCA analysis of the elements of unit vectors provides an approximate visual 260 
representation of similarity between systems. 261 
 In this study the comparison was performed between the biological systems of Eqs. (2-262 
4) and the chromatographic surrogates of Eqs (5-7) and that reported by Liu and coworkers 263 
[22] mentioned in section 1.3, further referred as MP3 system according to the designation 264 
used in the original paper. From the data presented in Table 3, it can be concluded that all 265 
biological systems have in common that the larger the molecular volume, the more favored 266 
brain uptake, followed in a lesser extent by the capacity of interactions through π- and n-267 
electrons. The coefficients of both permeability parameters, log PS and BBB0log P , are very 268 
similar with the exception of the solute hydrogen-bonding acidity, more negative for log PS. 269 
Concerning the comparison of chromatographic systems, differences between log k0.8% and 270 
log kMP3 were larger than expected, given that both ME were prepared in a similar way. 271 
Concerning the PCA plot shown in Figure 3, the chromatographic approaches assayed 272 
in the present work form a cluster, with the ME systems containing 0.8 and 1.6% of heptane 273 
being slightly closer to each other. Interestingly, although the physicochemical system used 274 
by Liu et al. (log kMP3) [22] was proposed as a surrogate of biological log BB, according to 275 
this PCA results it is much more similar to log PS, and the top left log BB seems to be far 276 
from the rest of all other systems, either biological or chromatographic. It must be pointed out 277 
that, according to the PCA loadings, the most relevant contribution to PC1 is the hydrogen-278 
bond basicity of the system (-0.33eu, 0.34su, 0.74au, -0.34bu, and 0.34vu), and therefore the 279 
systems with more negative au values lead to negative and similar PC1 digits (log BB, log PS, 280 
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and log kMP3), whereas the opposite trend is obtained for the less negative ones (log P0BBB, log 281 
k0%, log k0.8%, and log k1.6%).  282 
The quantitative estimation of differences between pairs of systems shown in Table 4 283 
confirms the significant difference between log k0.8% and log kMP3 observed on the PCA plot, 284 
much larger than initially expected taking into account that both ME were prepared in a 285 
similar way. The particular reasons leading to this mismatch are difficult to elucidate, but we 286 
provide here tentatively some of the possible explanations. Firstly, the representativity of the 287 
compounds used for correlations must be examined. In the present work the number of 288 
molecules included in the characterization set was larger than that of Liu (45 vs 26), and the 289 
studied log k range was wider (-0.848/1.203 vs -0.365/1.212). Another possible reason might 290 
lie in the chromatographic column used. Although both stationary phases were C18, the 291 
particular support and column technology might affect the retention of analytes (Gemini vs 292 
AT Chrom). Finally, the accuracy in the dead time measurement and thus in the determination 293 
of retention factors might have had an influence in the characterization (potassium bromide 294 
peak vs first significant deviation of the baseline).  295 
In relation to the biological systems, there is nearly the same distance from the three 296 
studied MELC systems to log BB and to log PS, with the distance to the latter being slightly 297 
shorter (Table 4). log PS and log P0BBB were initially expected to be closer to each other, 298 
since the latter is a correction of the former in order not to consider only the permeation of 299 
unionized species, which was very convenient in order to increase the number of compounds 300 
involved in the LFER characterization, but both of them are related to the BBB penetration. In 301 
order to find the possible reasons of this mismatch, a joint PCA was performed with the 302 
molecular descriptors (E, S, A, B, and V) of both sets of compounds included in the 303 
correlations of Eqs. (3) and (4), and the scores of the two main PC are plotted in Figure 4. 304 
Although the 30 substances included in log PS study show a reasonably good distribution 305 
over the two PCs, the higher number of compounds used for log P0BBB characterization allow 306 
a better coverage of the chemical diversity space, including molecules that broadened the 307 
range of hydrogen-bonding properties (A, 0.00/0.95 vs. 0.00/2.30; B, 0.48/2.55 vs 0.45/4.04) 308 
and π- and n-electrons interactions (E, 0.21/3.48 vs. 0.18/4.63).  309 
 When comparing the calculated distances between the chromatographic systems 310 
characterized in the present work and the biological BBB parameters, the highest similarity 311 
(i.e. the lowest distance) was obtained for the ME containing a 0.8% of heptane and BBB0log P  312 
(0.175). In contrast, the shortest distance with log BB was found to be 0.597 in the case of the 313 
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ME with a 1.6% of oil. Therefore, according to the LFER characterization, the 314 
chromatographic systems here studied seemed to be better models of BBB permeability (log 315 
PS/log P0BBB) rather than distribution (log BB) measurements, particularly the ME containing 316 
a 0.8% of heptane.  317 
 318 
3.4. MELC system as surrogate model for BBB 319 
The previous section shows that MELC systems can be good surrogate sytems for brain 320 
perfusion of non ionized compounds (log P0BBB), but many BBB active drugs are partially or 321 
totally ionized at the physiological blood pH. Thus, it would be very convenient to test MELC 322 
surrogation for ionized drugs.  323 
With the aim of assessing the predictive capacity of the proposed physicochemical 324 
system as a BBB model, several analytes with known log BB (Table 5) or log PS (Table 6) 325 
values were injected using as mobile phase the ME with a 0.8% of heptane. About only one-326 
fourth of the injected substances were unionized at pH 7.4, which corresponds to saline 327 
solutions employed in the brain perfusion assays, and therefore it was the selected pH for the 328 
chromatographic mobile phase, log PS data were used instead of log P0BBB as a measure of 329 
unidirectional brain penetration. Depending on the acid-base properties of the compounds an 330 
appropriate mobile phase pH might possibly allow an estimation of the penetration of 331 
unionized species, but these results could not be correlated with in vivo data since these 332 
experiments can be only performed at pH values close to the physiological one. Literature 333 
BBB values were plotted against obtained chromatographic retention factors (Figure 5) and 334 
after removing outliers from the correlations the following models for log BB and log PS 335 
were built:  336 
0.8%
2
log BB = 0.524(0.084) log 0.072(0.058)
( 42, 0.496, SD 0.34, 39)
k   
n R F

     (8) 337 
0.8%
2
log PS = 1.149(0.080) log 2.286(0.061)
( 40, 0.843, SD 0.39, 204)
k   
n R F

     (9) 338 
As expected from the LFER study, the MELC chromatographic system was not a good 339 
surrogate of log BB, since only 50% of the variance in log BB was predictable from retention 340 
factors and the slope of the regression is relatively low. In addition, compounds with extreme 341 
log BB values, either below -1.10 (ritonavir, flurbiprofen, didanosinec, salbutamol, atenolol) 342 
or above 1.15 (metoprolol, promazine, haloperidol, fluphenazine), were considered as outliers 343 
and thus the model failed in its modeling capacity. The standard deviation of the regression 344 
might appear to be acceptable (0.34), but it must be pointed out that the amplitude between 345 
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the lowest and the highest log BB values is only 2.25 units. In contrast, the chromatographic 346 
system explained log PS variance (84%) better and outliers were distributed along all the 347 
biological property range. In this case the standard deviation of the fitting was slightly higher 348 
(0.39), but in relation to a wider scale of log PS values (3.66 units). The presence of a 349 
relatively high number of outliers might be explained not only because of differences between 350 
biological and chromatographic systems, but also as a consequence of the experimental 351 
complexity of in situ brain perfusion experiments. In fact, from single compounds 352 
significantly different log PS values can be found in the literature. For instance, this was the 353 
case of the outlier sucrose, with reported log PS values in the range between -5.4 and -3.7, but 354 
also quercetin (-3.8 and -2.7) or quinidine (-3.7 and -2.7). In case of different data from single 355 
compounds, averaged log PS values were considered in the correlations, providing a rough 356 
estimate of its accuracy, but unfortunately for some solutes only single results were reported. 357 
It is also noteworthy to mention that the chromatographic system was intended to model 358 
passive permeation, and thus it should not be applied to molecules that might present any kind 359 
of active transport through the BBB. 360 
 Application of Eq. (9) to the different forms (neutral, zwitterionic or ionized) of acid 361 
and basic drugs of diverse structure means that MELC surrogation of blood-brain perfusion 362 
can be extended to all types of drugs regardless of drug charge or structure. Since both solvent 363 
media (MELC mobile phase and blood saline plasma) are mainly similar aqueous phases, 364 
drugs exhibit similar pKa values and degrees of ionization, surrogation can be extended to 365 
partially ionized drugs. This is an additional advantage of MELC for surrogation of biological 366 
systems over other surrogating HPLC mobile phases containing organic solvents.   367 
 368 
4. Conclusions 369 
 MELC systems of SDS+1-butanol+heptane at pH 7.4 have been characterized and 370 
compared to blood brain transport by the Abraham model. Increasing the heptane 371 
concentration up to 1.6% does not significantly changed the properties of the ME. The most 372 
relevant factor for solute retention was the molecular volume, suggesting a high affinity of 373 
large compounds for the C18 stationary phase. In contrast, dipolar/polarizable analytes and 374 
those with hydrogen-bonding basicity interacted preferably with the ME mobile phase, 375 
decreasing retention times. The oil concentration seemed to have a minor effect on 376 
interactions through π- and n-electrons and solute acidity by hydrogen-bonding, reducing 377 
retention as well but to a much lesser extent.  378 
13 
 
A chromatographic system consisting of a Gemini C18 column as stationary phase and a 379 
ME made of 50 mM phosphate buffer pH 7.4, 3.3% w/v SDS, 6.6% w/v of 1-butanol, and 380 
0.8% w/v of heptane as mobile phase is proposed as surrogate model for the rate of BBB 381 
penetration, particularly the logarithm of the passive permeability surface area product (log 382 
PS). Chromatographic retention factors (log k) of neutral and ionized drugs are directly and 383 
linearly related to log PS, without the need of any additional correction parameter.  384 
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Table 1. Intrinsic permeability values (log P0BBB) [5] and solute descriptors [25] of the 
compounds used on Eq. (4) 
Compound BBB0log P  E S A B V 
1-Aminocyclohexanecarboxylic acid* -5.99 0.56 0.98 0.78 0.93 1.16 
3-Hydroxyanthranilic acid* -2.72 1.28 1.38 1.03 0.83 1.09 
3-Hydroxykyunrenine -6.49 1.70 2.19 1.31 1.71 1.63 
5-F-Uracil -5.67 0.97 1.29 1.17 0.99 0.77 
Acetamide -5.05 0.48 0.36 0.31 0.45 0.51 
Adenosine* -4.80 2.69 2.64 0.97 2.22 1.75 
Aldosterone -5.46 2.13 3.35 0.48 1.91 2.75 
Amantadine* -1.20 0.84 0.68 0.21 0.64 1.29 
Aminoguanidine -5.85 0.95 0.69 0.69 1.47 0.61 
Aminopyrine -3.30 1.78 1.78 0.00 1.60 1.87 
Amitriptyline -1.48 2.25 1.78 0.00 1.00 2.40 
Amoxapine -2.75 2.25 1.68 0.16 1.43 2.25 
Anthranilic acid -4.91 1.08 1.48 0.74 0.50 1.03 
Antipyrine -4.00 1.32 1.50 0.00 1.48 1.48 
Arabinose -6.63 0.98 1.55 0.94 1.52 1.06 
Ascorbic acid* -2.54 1.23 1.68 1.12 1.65 1.11 
Atomoxetine -1.27 1.37 1.36 0.13 0.90 2.19 
Brompheniramine -1.70 1.70 1.57 0.00 1.02 2.26 
Bupropion -2.09 1.14 1.30 0.09 1.02 1.94 
Butanediol -5.03 0.42 0.71 0.63 0.62 0.79 
Butanol -2.88 0.22 0.42 0.37 0.48 0.73 
Butyric acid* -2.15 0.21 0.64 0.61 0.45 0.75 
Caffeine -3.90 1.50 1.72 0.05 1.28 1.36 
Carbamazepine -3.74 2.15 2.11 0.53 1.10 1.81 
Carmustine -3.81 0.83 2.06 0.16 0.77 1.39 
Cetirizine* -5.80 2.05 2.24 0.57 1.76 2.94 
Chlorambucil* -0.80 1.22 1.60 0.57 0.80 2.26 
Chlorpheniramine -1.84 1.47 1.34 0.00 1.35 2.21 
Chlorpromazine -1.33 2.20 1.83 0.00 0.94 2.41 
Cimetidine -5.92 1.70 1.73 0.67 2.21 1.96 
Citalopram -2.07 1.66 1.87 0.00 1.08 2.53 
Clemastine -0.96 1.70 1.55 0.00 0.97 2.76 
Clozapine -2.66 2.46 1.82 0.18 1.44 2.43 
Colchicine* -5.20 2.23 2.59 0.31 1.95 2.99 
Corticosterone -4.29 1.86 3.43 0.40 1.63 2.74 
Creatinine* -6.60 1.03 0.51 0.31 1.07 0.84 
DADLE -6.80 3.01 5.54 2.30 3.76 4.41 
Daunomycine* -2.40 3.59 3.53 0.93 3.06 3.67 
DDEP -3.60 2.39 2.09 0.45 0.98 1.97 
DDMP -3.47 2.39 2.08 0.45 0.98 1.83 
Dianhydrogalactitol -5.60 0.98 1.09 0.46 1.18 0.97 
2 
 
Diazepam -3.30 2.08 1.57 0.00 1.25 2.07 
Dibromodulcitol -5.72 1.44 1.65 1.23 1.26 1.54 
Diphenhydramine -1.94 1.36 1.43 0.00 0.95 2.19 
Donepezil -1.68 2.12 2.49 0.00 1.50 3.03 
Dopamine* -2.68 1.35 1.46 1.20 1.04 1.22 
Doxepin -1.24 1.75 1.46 0.00 0.98 2.32 
Doxorubicin -4.00 3.75 3.69 1.17 3.34 3.73 
DPDPE -5.60 3.87 5.81 2.30 4.04 4.77 
Ehylene glycol -5.30 0.40 0.90 0.58 0.78 0.51 
Ergotamine -3.82 4.63 3.87 0.85 3.56 4.21 
Erythritol -6.90 0.62 1.20 0.83 1.45 0.91 
Estradiol -3.30 1.80 1.77 0.86 1.10 2.20 
Ethanol -3.40 0.25 0.42 0.37 0.48 0.45 
Ethosuximide -4.46 0.74 0.94 0.34 0.93 1.12 
Fexofenadine* -6.60 2.72 2.48 1.20 2.12 4.09 
Fluoxetine -1.10 1.01 1.19 0.13 0.78 2.24 
Fluphenazine -3.35 2.16 2.30 0.26 1.80 3.09 
Flurbiprofen* -0.58 1.50 1.51 0.57 0.58 1.84 
Fluvastatin -2.28 2.75 2.48 1.20 1.46 3.13 
Formamide -5.72 0.47 1.30 0.64 0.57 0.37 
Fructose -6.80 1.30 1.61 1.31 1.83 1.20 
Ftorafur -5.02 1.05 1.66 0.24 1.14 1.28 
Gabapentin -4.56 0.56 0.99 0.78 0.93 1.44 
Galactitol -6.70 1.23 1.75 1.62 1.81 1.31 
Glibenclamide -3.24 2.81 2.52 0.99 2.07 3.56 
Glucose* -4.50 1.34 1.64 1.31 1.85 1.20 
Glycerol -5.40 0.51 0.76 0.47 1.43 0.71 
Glycine -5.50 0.37 0.93 0.78 0.90 0.56 
Grepafloxacin -4.86 2.23 2.43 0.73 1.88 2.59 
Guanidine -5.60 0.60 0.86 0.36 1.24 0.51 
Haloperidol -2.46 1.90 1.39 0.40 1.76 2.80 
Hexanoic acid* -1.31 0.17 0.63 0.62 0.44 1.03 
Hispidulin -3.11 2.30 2.32 0.96 1.20 2.05 
Hydrocortisone -5.85 2.03 3.49 0.71 1.90 2.80 
Hydroxyzine -3.04 2.00 2.21 0.10 1.89 2.92 
Hypoxanthine -5.46 1.65 1.68 0.44 1.04 0.88 
Inulin -7.35 2.28 2.60 2.01 3.41 2.23 
Iodoacetamide -4.10 1.03 1.37 0.49 0.60 0.76 
Iodoantipyrine -3.20 2.01 1.98 0.00 1.31 1.74 
Isocarboxazid* -3.22 1.61 2.16 0.39 1.38 1.74 
Isopropanol -3.66 0.21 0.36 0.33 0.56 0.59 
L-Alanine -5.44 0.38 0.92 0.78 0.93 0.71 
Lamotrigine -4.67 2.27 2.03 0.35 0.96 1.65 
L-Arginine -4.64 1.06 1.24 1.26 1.95 1.38 
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L-Aspartic acid -6.66 0.55 1.37 1.18 1.26 0.92 
Levodopa* -3.90 1.33 1.77 1.56 1.44 1.43 
 L-Glutamic acid -6.26 0.55 1.37 1.35 1.26 1.06 
L-Glutamine -5.28 0.86 1.12 1.09 1.35 1.10 
L-Histidine* -4.28 1.02 1.74 1.13 1.41 1.13 
Lidocaine -3.24 1.01 1.50 0.12 1.21 2.06 
L-Isoleucine -4.16 0.39 0.92 0.78 0.97 1.13 
L-Kynurenine -6.16 1.50 2.06 0.96 1.60 1.57 
L-Lysine -4.93 0.58 1.26 0.99 1.48 1.23 
L-Methionine -4.39 0.72 1.08 0.78 1.06 1.15 
Lomustine -4.00 0.93 2.00 0.16 0.79 1.72 
Loratidine* -4.00 2.19 2.09 0.00 1.14 2.87 
L-Ornithine -4.68 0.58 1.25 0.99 1.48 1.09 
Lovastatin acid -2.53 1.39 1.84 1.20 1.62 3.45 
Lovastatin* -3.42 1.38 2.34 0.31 1.44 3.29 
Loxapine -3.36 2.30 1.67 0.00 1.49 2.39 
L-Threonine -5.21 0.61 1.14 1.03 1.33 0.91 
L-Tryptophan -4.22 1.62 1.80 1.09 1.23 1.54 
L-Tyrosine -3.90 1.18 1.60 1.28 1.29 1.37 
L-Valine -4.68 0.39 0.92 0.78 0.97 0.99 
Mannitol -6.90 0.84 2.26 0.86 1.79 1.31 
Maprotiline -0.40 1.76 1.27 0.13 0.68 2.33 
Melphalan* -5.27 1.43 1.90 0.78 1.37 2.22 
Meprobamate -5.09 0.71 1.62 0.89 1.12 1.73 
Mesoridazine* -1.41 2.87 2.97 0.00 1.69 2.96 
Methanol -3.66 0.28 0.44 0.43 0.47 0.31 
Methotrexate -5.40 3.51 4.23 1.85 2.82 3.22 
Methylurea -5.70 0.53 1.14 0.59 0.70 0.61 
Metoclopramide -2.86 1.59 1.57 0.54 1.50 2.34 
Midazolam -3.11 2.57 2.01 0.00 1.38 2.26 
Mirtazapine -2.75 2.08 1.67 0.00 1.22 2.11 
Naproxen* -0.77 1.51 1.98 0.60 0.68 1.78 
Naringenin -3.96 2.23 2.19 1.30 1.14 1.89 
Nicotinamide -4.88 1.01 1.09 0.63 1.00 0.93 
Octanoic acid* -1.14 0.15 0.65 0.62 0.45 1.31 
Olanzapine -2.73 2.30 1.59 0.13 1.45 2.37 
Oxycodone -3.40 2.18 2.28 0.23 1.80 2.26 
PCNU -4.86 1.47 2.72 0.50 1.66 1.71 
Pemoline -5.45 1.48 1.45 0.21 1.22 1.26 
Pentazocine* -3.69 1.54 1.13 0.50 1.04 2.45 
Pergolide -1.14 2.22 1.48 0.31 1.01 2.54 
Perphenazine -2.61 2.87 2.33 0.23 1.84 3.02 
Phenelzine -4.32 0.98 1.02 0.34 0.99 1.20 
Phenytoine -4.09 1.71 2.19 0.85 1.00 1.87 
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Pramipexole -2.70 1.35 1.35 0.36 0.97 1.68 
Procarbazine -4.62 1.22 1.79 0.52 1.59 1.88 
Progesterone -3.74 1.45 3.29 0.00 1.14 2.62 
Propranolol* -1.30 1.88 1.43 0.17 1.42 2.15 
Propylene glycol -4.49 0.37 0.90 0.58 0.80 0.65 
Pyrilamine -2.90 1.82 1.92 0.00 1.59 2.39 
Pyrimethamine -3.57 1.90 0.98 0.34 1.36 1.85 
Quercetin -4.70 2.68 2.64 1.88 1.63 1.96 
Quetiapine -3.06 2.72 1.93 0.23 2.01 2.91 
Quinidine -3.90 2.40 1.71 0.23 1.81 2.55 
Quinine -3.45 2.47 1.23 0.37 1.97 2.55 
Quinolinic acid -6.26 0.99 1.59 1.14 1.06 1.11 
Rimantadine* 0.13 0.84 0.67 0.21 0.68 1.57 
Rimonabant -3.60 3.38 3.13 0.26 1.55 3.21 
Risperidone -2.94 2.59 2.23 0.00 1.70 3.04 
Rizatriptan -4.43 2.21 2.05 0.31 1.28 2.14 
Salicylic acid* -1.02 0.89 0.84 0.71 0.38 0.99 
Selegiline -3.12 1.00 1.00 0.09 0.71 1.72 
Sucrose -6.90 1.97 2.50 2.10 3.00 2.23 
Sumatriptan -5.06 1.87 2.28 0.85 1.88 2.27 
Tacrine -1.51 1.61 0.94 0.13 0.61 1.60 
Temazepam -3.35 2.29 1.55 0.12 1.70 2.13 
Terfenadine -0.92 2.55 2.04 0.63 1.80 4.01 
Testosterone -3.40 1.54 2.59 0.32 1.19 2.38 
Theobromine -5.00 1.50 1.60 0.50 1.38 1.22 
Theophylline -5.00 1.50 1.60 0.54 1.34 1.22 
Thioridazine -1.95 2.70 2.10 0.00 1.30 2.90 
Thiothixene -2.35 2.94 2.59 0.00 2.19 3.36 
Thiourea -5.50 0.84 0.82 0.77 0.87 0.57 
Thymidine -5.84 1.78 2.01 0.81 2.11 1.66 
Thymine -3.93 1.09 1.23 1.00 1.01 0.89 
Tiagabine* -4.45 1.77 1.60 0.57 1.02 2.89 
Tolbutamide -2.64 1.44 1.61 0.68 1.33 2.06 
Trazodone -3.13 2.64 2.47 0.00 1.92 2.73 
Trifluoperazine -3.00 2.00 1.80 0.00 1.50 2.89 
Trimethylene glycol -5.40 0.40 0.91 0.77 0.85 0.65 
TYR-MIF-1 -5.78 2.59 4.80 1.71 3.30 3.48 
Urea -6.00 0.74 0.57 0.52 0.87 0.46 
Valproic acid -2.00 0.18 0.60 0.61 0.45 1.31 
Warfarin* -1.56 2.30 2.18 0.35 1.49 2.31 
Xanthine -5.62 1.50 1.60 0.97 1.07 0.94 
Zaleplon -4.25 2.36 2.60 0.00 1.42 2.31 
Ziprasidone -3.25 3.38 2.67 0.48 1.65 2.92 
Minimum -7.35 0.15 0.36 0.00 0.38 0.31
5 
 
Maximum 0.13 4.63 5.81 2.30 4.04 4.77
Median -3.90 1.50 1.63 0.52 1.28 1.84
Average -3.89 1.58 1.76 0.60 1.36 1.89
SD 1.66 0.85 0.87 0.50 0.64 0.92
Average BBB0log P  is reported in case of different literature values for the same compound. 
Experimental molecular descriptors marked in bold. 




Table 2. Molecular descriptors [25] and measured retention factors of the compounds used for 
the characterization of the chromatographic systems containing 0, 0.8, and 1.6% of heptane 
(w/v).  
Compound 
Molecular descriptorsa log kb 
E S A B V 0% 0.8% 1.6% 
1,2,4-trimethylbenzene 0.68 0.56 0.00 0.19 1.14 1.119 1.116 1.071 
2-nitroanisole 0.97 1.34 0.00 0.45 1.09 0.419 0.425 0.380 
4-chloroacetanilide 0.98 1.47 0.64 0.51 1.24 0.358 0.346 0.199 
Acetamide 0.46 1.30 0.54 0.68 0.51 -1.200 -0.848 -0.888 
Acetanilide 0.90 1.39 0.48 0.67 1.11 0.057 0.070 -0.022 
Acetophenone 0.82 1.01 0.00 0.48 1.01 0.410 0.449 0.440 
Aminopyrene 1.78 1.78 0.00 1.60 1.87 -0.162 -0.120 -0.182 
Anisole 0.71 0.75 0.00 0.29 0.92 0.788 0.827 0.832 
Anthracene 2.29 1.34 0.00 0.28 1.45 1.144 1.081 1.027 
Antipyrine 1.32 1.50 0.00 1.48 1.48 -0.365 -0.281 -0.366 
Benzaldehyde 0.82 1.00 0.00 0.39 0.87 0.390 0.436 0.442 
Benzamide 0.99 1.50 0.49 0.67 0.97 -0.120 -0.106 -0.192 
Benzene 0.61 0.52 0.00 0.14 0.72 0.866 0.908 0.928 
Benzofuran 0.89 0.83 0.00 0.15 0.91 0.934 0.936 0.919 
Benzyl alcohol 0.80 0.87 0.39 0.56 0.92 0.104 0.124 0.046 
Bromobenzene 0.88 0.73 0.00 0.09 0.89 1.000 0.991 0.977 
Butanone 0.17 0.70 0.00 0.51 0.69 -0.297 -0.178 -0.162 
Butylbenzene 0.60 0.51 0.00 0.15 1.28 1.170 1.149 1.096 
Butyrophenone 0.80 0.95 0.00 0.51 1.30 0.839 0.838 0.815 
Caffeine 1.50 1.72 0.05 1.28 1.36 -0.663 -0.533 -0.606 
Carbamazepine 2.15 2.11 0.53 1.10 1.81 0.212 0.197 0.068 
Celecoxib 2.51 2.43 0.44 1.22 2.47 0.732 0.653 0.447 
Cortisone 1.96 3.50 0.36 1.87 2.76 0.008 -0.004 -0.105 
Coumarin 1.06 1.76 0.00 0.43 1.06 0.219 0.224 0.163 
Diazepam 2.08 1.57 0.00 1.25 2.07 0.459 0.424 0.274 
Ethylbenzene 0.61 0.51 0.00 0.15 1.00 1.061 1.052 1.037 
Flunitrazepam 2.10 2.15 0.00 1.48 2.14 0.333 0.314 0.180 
Hydrocortisone 2.03 3.50 0.71 1.90 2.80 0.041 0.026 -0.109 
Lamotrigine 2.27 2.03 0.35 0.96 1.65 0.153 0.186 0.074 
Loratadine 2.19 2.09 0.00 1.14 2.87 0.857 0.772 0.548 
N,N-dimethylacetamide 0.36 1.35 0.00 0.77 0.79 -0.954 -0.710 -0.782 
Naphthalene 1.34 0.92 0.00 0.20 1.09 1.043 1.019 0.997 
Nitrobenzene 0.87 1.11 0.00 0.28 0.89 0.621 0.631 0.631 
N-phenylurea 1.11 1.33 0.79 0.79 1.07 0.005 0.020 -0.084 
Omeprazole 2.67 3.18 0.35 2.05 2.52 0.349 0.346 0.186 
Paracetamol 1.06 1.63 1.04 0.86 1.17 -0.609 -0.461 -0.547 
Pentachloronitrobenzene 1.47 1.70 0.00 0.01 1.50 1.248 1.203 1.113 
Phenanthrene 2.06 1.29 0.00 0.29 1.45 1.132 1.095 1.018 
Prednisolone 2.21 3.10 0.71 1.92 2.76 0.066 0.034 -0.083 
Pregnenolone 1.36 3.29 0.32 1.18 2.67 0.778 0.700 0.519 
Progesterone 1.45 3.29 0.00 1.14 2.62 0.671 0.606 0.473 
Propiophenone 0.80 0.95 0.00 0.51 1.16 0.666 0.683 0.685 
Propylbenzene 0.60 0.50 0.00 0.15 1.14 1.127 1.119 1.073 
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Pyrene 2.60 1.52 0.00 0.25 1.59 1.156 1.111 1.021 
Pyrrole 0.61 0.91 0.22 0.25 0.58 -0.039 0.012 -0.031 
Riluzole 1.36 1.45 0.23 0.67 1.32 0.584 0.588 0.422 
Rofecoxib 1.66 2.43 0.00 1.15 2.23 0.093 0.120 0.000 
Theophylline 1.50 1.60 0.54 1.34 1.22 -0.812 -0.587 -0.680 
Toluene 0.60 0.52 0.00 0.14 0.86 0.985 0.998 0.996 
Valerophenone 0.80 0.95 0.00 0.50 1.44 0.957 0.940 0.897 
Minimum 0.17 0.50 0.00 0.01 0.51 -1.200 -0.848 -0.888
Maximum 2.67 3.50 1.04 2.05 2.87 1.248 1.203 1.113
aExperimental molecular descriptors marked in bold. 
bMean log k values obtained from triplicate injections, with SD below 0.01 in all cases. 
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Table 3. LFER system coefficients of unit vectors. 
 eu su au bu vu 
log BB 0.308 -0.534 -0.436 -0.401 0.519 
log PS 0.097 -0.314 -0.590 -0.510 0.532 
log P0BBB 0.080 -0.353 -0.163 -0.558 0.728 
log kMP3 0.059 -0.373 -0.533 -0.550 0.521 
log k1.6% -0.006 -0.241 -0.163 -0.660 0.692 
log k0.8% -0.006 -0.237 -0.136 -0.652 0.708 




Table 4. Distances between pairs of studied systems. 
 log BB log PS log P0
BBB log kMP3 log k1.6% log k0.8% 
log BB 0 - - - - - 
log PS 0.358 0 - - - - 
log P0BBB 0.477 0.474 0 - - - 
log kMP3 0.345 0.100 0.425 0 - - 
log k1.6% 0.597 0.497 0.178 0.447 0 - 
log k0.8% 0.612 0.523 0.175 0.475 0.033 0 




Table 5. Biological log BB values [8] and their corresponding measured retention factors in 
the chromatographic system containing 0.8% of heptane (w/v). 
Compounds log BB log k0.8%a
Ionization at pH 7.4b 
Neutral Zwitterionic Negative Positive 
1,2,4-trimethylbenzene 0.16 1.116 100% 0% 0% 0% 
1,2-dimethylbenzene 0.30 1.064 100% 0% 0% 0% 
1,3-dimethylbenzene 0.29 1.049 100% 0% 0% 0% 
1,4-dimethylbenzene 0.31 1.045 100% 0% 0% 0% 
Acetazolamide -0.52 -0.934 43% 0% 57% 0% 
Acyclovir -0.50 -0.906 78% 0% 0% 22% 
Alprenolol -0.23 0.779 1% 0% 0% 99% 
Aminopyrene 0.00 -0.120 100% 0% 0% 0% 
Amiodaronec -1.08 1.002 4% 0% 0% 96% 
Amitriptyline 0.90 0.860 4% 0% 0% 96% 
Amprenavir -0.56 0.271 100% 0% 0% 0% 
Antipyrine -0.10 -0.281 100% 0% 0% 0% 
Atenololc -1.12 -0.012 1% 0% 0% 99% 
Atropine -0.06 0.383 1% 0% 0% 99% 
Barbital -0.14 -0.221 100% 0% 0% 0% 
Benzene 0.37 0.908 100% 0% 0% 0% 
Butanone -0.08 -0.178 100% 0% 0% 0% 
Caffeine -0.06 -0.533 100% 0% 0% 0% 
Carbamazepine -0.11 0.197 100% 0% 0% 0% 
Celecoxibc -1.00 0.653 100% 0% 0% 0% 
Clobazam 0.35 0.274 100% 0% 0% 0% 
Codeine 0.55 0.142 13% 0% 0% 87% 
Diazepam 0.48 0.424 100% 0% 0% 0% 
Didanosinec -1.30 -0.832 97% 0% 3% 0% 
Ethylbenzene 0.20 1.052 100% 0% 0% 0% 
Flunitrazepam 0.06 0.314 100% 0% 0% 0% 
Fluphenazinec 1.51 0.851 25% 0% 0% 75% 
Flurbiprofenc -1.68 -0.011 0% 0% 100% 0% 
Haloperidolc 1.32 1.090 5% 0% 0% 95% 
Ibuprofen -0.18 0.061 0% 0% 100% 0% 
Imipramine 1.01 0.841 2% 0% 0% 98% 
Lamotrigine 0.36 0.186 0% 0% 0% 100% 
Lidocaine 0.34 0.585 14% 0% 0% 86% 
Metoprololc 1.15 0.536 1% 0% 0% 99% 
Nevirapine 0.00 0.151 100% 0% 0% 0% 
Nicotine 0.56 0.129 11% 0% 0% 89% 
Paracetamol -0.42 -0.461 100% 0% 0% 0% 
Pindolol -0.15 0.312 1% 0% 0% 99% 
Promazinec 1.23 0.786 2% 0% 0% 98% 
Propranolol 0.88 0.685 1% 0% 0% 99% 
Pyrene 0.23 1.111 100% 0% 0% 0% 
Pyrilamine 0.49 0.632 4% 0% 0% 96% 
Quinidine -0.32 0.733 6% 0% 0% 94% 
Riluzole 0.30 0.588 100% 0% 0% 0% 
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Ritonavirc -1.82 0.831 100% 0% 0% 0% 
Salbutamolc -1.17 0.100 2% 1% 0% 97% 
Salicylic acid -1.10 -1.064 0% 0% 100% 0% 
Saquinavirc -0.86 0.901 87% 0% 0% 13% 
Stavudine -0.48 -0.793 93% 0% 7% 0% 
Terfenadine 1.15 1.300 1% 0% 0% 99% 
Theophylline -0.31 -0.587 95% 0% 5% 0% 
Toluene 0.37 0.998 100% 0% 0% 0% 
Trazodone -0.22 0.484 83% 0% 0% 17% 
Zidovudine -0.77 -0.457 99% 0% 1% 0% 
aMean log k values obtained from triplicate injections, with SD below 0.01 in all cases. 
bNeutral, zwitterionic, negative and positive fraction calculated from GALAS algorithm [25]. 




Table 6. Biological log PS values [5] and their corresponding measured retention factors in 
the chromatographic system containing 0.8% of heptane (w/v). 
Compounds log PS log k0.8%a 
Ionization at pH 7.4b 
Neutral Zwitterionic Negative Positive 
5-F-Uracil -3.77 -0.916 72% 0% 28% 0% 
Acetamide -3.05 -0.848 100% 0% 0% 0% 
Aminopyrinec -1.30 -0.120 100% 0% 0% 0% 
Amitriptyline -1.02 0.860 4% 0% 0% 96% 
Anthranilic acidc -2.92 -1.389 0% 1% 0% 99% 
Antipyrine -1.94 -0.281 100% 0% 0% 0% 
Caffeinec -1.83 -0.533 100% 0% 0% 0% 
Carbamazepine -1.74 0.197 100% 0% 0% 0% 
Corticosterone -2.28 0.125 100% 0% 0% 0% 
Diazepam -1.27 0.424 100% 0% 0% 0% 
Diphenhydramine -1.24 0.739 5% 0% 0% 95% 
Estradiol -1.08 0.393 100% 0% 0% 0% 
Fluphenazine -1.87 0.851 25% 0% 0% 75% 
Flurbiprofen -1.80 -0.011 0% 0% 100% 0% 
Formamide -3.72 -0.818 100% 0% 0% 0% 
Glibenclamide -2.77 0.117 7% 0% 93% 0% 
Glycine -3.49 -0.930 0% 100% 0% 0% 
Haloperidol -1.45 1.090 5% 0% 0% 95% 
Hydrocortisonec -3.85 0.026 100% 0% 0% 0% 
Ibuprofen -2.03 0.061 0% 0% 100% 0% 
Indinavirc -3.73 0.559 96% 0% 0% 4% 
L-Alaninec -3.44 -0.109 0% 100% 0% 0% 
Lamotrigine -2.68 0.186 0% 0% 0% 100% 
L-Arginine -2.64 -0.127 0% 3% 0% 97% 
L-Aspartic acid -4.66 -1.856 0% 0% 100% 0% 
L-Glutamic acid -4.26 -1.898 0% 0% 100% 0% 
L-Glutamine -3.28 -0.963 0% 99% 1% 0% 
Lidocaine -1.90 0.585 14% 0% 0% 86% 
L-Lysine -2.92 -0.115 0% 0% 100% 0% 
L-Tryptophan -2.23 -0.260 0% 98% 2% 0% 
L-Tyrosinec -1.91 -0.777 0% 98% 2% 0% 
L-Valine -2.68 -0.113 0% 100% 0% 0% 
Maprotiline -1.35 0.889 0% 0% 0% 100% 
Naringenin -1.98 0.053 59% 0% 41% 0% 
Nicotinamide -2.88 -0.635 98% 0% 0% 2% 
Perphenazine -1.25 0.805 25% 0% 0% 75% 
Progesterone -1.74 0.606 100% 0% 0% 0% 
Propranolol -1.00 0.685 1% 0% 0% 99% 
Pyrilamine -1.82 0.632 4% 0% 0% 96% 
Quercetinc -3.05 0.122 64% 0% 36% 0% 
Quetiapine -1.31 0.543 99% 0% 0% 1% 
Quinidinec -2.92 0.733 6% 0% 0% 94% 
Salicylic acid -3.40 -1.064 0% 0% 100% 0% 
Sucrosec -4.52 0.271 100% 0% 0% 0% 
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Terfenadine -1.39 1.300 1% 0% 0% 99% 
Testosterone -1.31 0.387 100% 0% 0% 0% 
Theophylline -2.96 -0.587 95% 0% 5% 0% 
Thiourea -3.52 -0.768 100% 0% 0% 0% 
Thyminec -1.93 -0.632 99% 0% 1% 0% 
Trazodone -1.46 0.484 83% 0% 0% 17% 
Verapamil -1.76 0.644 5% 0% 0% 95% 
aMean log k values obtained from triplicate injections, with SD below 0.01 in all cases. 
bNeutral, zwitterionic, negative and positive fraction calculated from GALAS algorithm [25]. 
cExcluded from correlation on Eq. (9). 





Figure 1. Plot of observed vs. calculated intrinsic permeability values. Empty symbols show 
compounds excluded from correlation.  
 
Figure 2. Plot of observed vs. calculated retention factors of the assayed chromatographic 
systems. Empty symbols show compounds excluded from correlations (loratadine, N,N-
dimethylacetamide, omeprazole, and rofecoxib were excluded in all systems). 
 
Figure 3. Plot of the first two scores of the PCA of the compared biological (Eqs. 2-4) and 
chromatographic BBB systems (Eq. 5-7 and log kMP3 [22]). 
 
Figure 4. Joint PCA analysis of compounds used in log PS (empty squares) and log P0BBB 
(full circles) correlations. 
 
Figure 5. Plot of biological BBB distribution (log BB) and permeation (log PS) values vs. 
retention factors obtained for the chromatographic system containing a 0.8% of heptane at pH 
7.4. Legend: (●) unionized, (▼) zwitterionic, (■) totally or partially negatively charged, (▲) 
totally or partially positively charged, and (x) compounds excluded from correlations. 
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